JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[The angiographic classification and endovascular therapy of the vein of Galen aneurysmal malformation].

We treated 11 cases of the vein of Galen aneurysmal malformation, one of which was diagnosed by MRI only, and 10 underwent CAG diagnostic procedure. Among the 10 CAG diagnosed cases, 5 were classified as the vein of Galen aneurysmal malformation (VGAM) with the AV shunt directing to the vein of Galen. The other 5 were classified as the vein of Galen aneurysmal dilitation (VGAD) secondary to parenchymal AVM or dural AVF. 8 cases underwent endovascular treatment. For VGAM, the shunts in the wall of the vein were embolized. For VGAD, the primary AVM or AVF were embolized. The pathphysiology, angiographic characteristics, classification and the principle of endovascular therapy of the vein of Galen aneurysmal malformation were discussed.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app